about
Arterial structure and function in inflammatory bowel diseaseCatabolic effects of thyroid hormone excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown.Renal involvement in leishmaniasis: a review of the literatureOxidative stress and cellular stress response in diabetic nephropathy.The Neural Baroreflex Pathway in Subjects With Metabolic Syndrome: A Sub-Study of the Paris Prospective Study III.Physical performance and clinical outcomes in dialysis patients: a secondary analysis of the EXCITE trial.Arterial stiffness in inflammatory bowel disease: a systematic review and meta-analysis.A systematic review of arterial stiffness, wave reflection and air pollution.Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.Seasonal variations of hyponatremia in the emergency department: Age-related changes.Kidney and heavy metals - The role of environmental exposure (Review).Serum sodium correction rate and the outcome in severe hyponatremia.Diseases associated with electrolyte imbalance in the ED: age-related differences.Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial.A Case Report of an Atypical Presentation of IgG4-Related Disease and Idiopathic CD4 Lymphocytopenia.Non-hemodynamically significant renal artery stenosis predicts cardiovascular events in persons with ischemic heart disease.Fitness for entering a simple exercise program and mortality: a study corollary to the exercise introduction to enhance performance in dialysis (EXCITE) trial.Detection of pulmonary congestion by chest ultrasound in dialysis patients.Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.The effect of tumor necrosis factor antagonists on functional aortic stiffening.Long term effects of low protein diet on depressive symptoms and quality of life in elderly Type 2 diabetic patients.Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3.Maintenance therapy with salicylates is associated with aortic stiffening in patients with inflammatory bowel disease.Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.Increased cardiovascular risk in subjects with a low prevalence of classic cardiovascular risk factors: The inflammatory bowel disease paradoxIncreased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugsArterial stiffness is increased in patients with inflammatory bowel diseaseErratum to: Prevalence of renal artery stenosis in patients undergoing cardiac catheterizationEffect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical TrialGlobal approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for interventionHepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal DiseaseRenal function and ultrasound imaging in elderly subjects[Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD]Renal artery diameter, renal function and resistant hypertension in patients with low-to-moderate renal artery stenosisClinical Challenges and Images in GIPulse Pressure Is an Independent Predictor of Aortic Stiffness in Patients with Mild to Moderate Chronic Kidney DiseaseEffect of plasma amino acid and hormone concentrations on renal plasma flow and glomerular filtration rateRenal hemodynamics in renal transplant recipients. The role of reduced kidney mass and cyclosporine administrationComparison of the effects of human recombinant insulin-like growth factor I and insulin on plasma amino acid concentrations and leucine kinetics in humansDifferential effects of amino acid and ketoacid on protein metabolism in humans
P50
Q26777549-0E497337-2182-43D4-B562-350695CB8E93Q34559495-8D690711-3BA6-47AA-A7B8-C49C373DA120Q35574387-9E395C4F-C269-4940-9683-162E2B92CBB6Q36259336-CA6D7F71-6B42-400E-8A52-982D004201E3Q36478190-D66402C2-81B4-4146-BAE1-238E3B930E2EQ38425427-FC5C05D0-3DCC-4B49-98A2-851043C4EBB8Q38735750-3CEFF45D-8DC0-4F65-B32E-450A13667AEEQ38871430-5C4EA122-C6BD-46C1-A86A-C4CC4EF6896DQ38991938-A79A43DE-E0D8-4A36-8893-89A58149F8CAQ38993786-A1906C58-7F2C-4D70-99AF-9A225A1A378CQ39198635-30D8A2DC-1636-4F3C-8B06-8F0C98571311Q39363179-BD15B028-5021-4E3E-9D4F-61B78D4FF3AEQ39542787-92646AA8-B537-4F4D-972A-CB84751C5445Q40445746-59C49A9E-D9D2-4112-AF1E-2083AFE9ACF7Q40941193-944A4DE0-77A1-45E2-BB59-57D5B3528255Q41695051-E1D17C21-3A9A-4889-AD37-77A4C6EE29D3Q44422807-ABD5781C-7AF3-4D18-98CA-280D87197828Q45082421-E8C9A27D-E348-496C-97D5-AC8A747B0F25Q46948629-00E96432-8F9B-4CD1-A00B-53A841B575F2Q48332443-C2DFA7AA-2030-450C-8507-45F51ABD9BA1Q48433175-0B8224A7-7D15-4D74-BBAE-DE387DCC600CQ53476226-C25F9875-D9F8-4B0A-A62D-3AD090E64A9EQ53725017-F87B2A00-0186-4868-AC61-96E168ED9363Q55404441-5F5E659D-BF77-4E7A-89A5-E95335222522Q57662335-BF85C15E-1571-46C6-9458-126F58B81631Q57662343-CAD5CC56-62CE-4DFB-867B-39848AD8004FQ57662373-AC388E2B-1BFC-4FB9-914C-07D970FF7042Q57764322-E28131B5-CE31-497F-ABB1-A8D23B258BB8Q57764386-F335F4A6-BE67-4E25-8EA6-7E2219FDFC7BQ58949564-F7888144-A0A6-4962-8C5F-7C0D1692D64FQ58950388-CA260A8B-1795-4310-9506-19A6D424F643Q59100939-005D1C73-CA4A-4A80-AF38-927F33A65C1AQ60628031-C8324ED5-64CC-4353-B5FF-BD97B4B34A2EQ60628043-17C78198-D106-4AF2-B5E5-9DD38B7EDA65Q60793346-1B132634-B6C3-427C-B845-3115B278F85DQ63435865-A23F2E98-99A1-4FC0-AA07-5A35EB323191Q69928683-4E3B1413-8A6B-4643-8B85-C7A2D3E5D621Q71015119-1DF4C6D2-6E3C-4DFD-A9A6-A9D07A737220Q72053268-045F77A4-79C9-405A-AEAE-E6714F39DABAQ73447207-3CBC40C5-4D86-4639-B91E-22F2C9D3828A
P50
description
researcher, ORCID id # 0000-0002-9014-2007
@en
wetenschapper
@nl
name
Pietro Castellino
@ast
Pietro Castellino
@en
Pietro Castellino
@es
Pietro Castellino
@nl
type
label
Pietro Castellino
@ast
Pietro Castellino
@en
Pietro Castellino
@es
Pietro Castellino
@nl
prefLabel
Pietro Castellino
@ast
Pietro Castellino
@en
Pietro Castellino
@es
Pietro Castellino
@nl
P106
P1153
22937064600
P31
P496
0000-0002-9014-2007